Navigation Links
Chemoembolization Improving as Liver Cancer Treatment
Date:1/19/2009

these microspheres absorb the chemotherapeutic agent, and then the drug is released directly into the tumor.

A month after treatment, tumors in 27 of the patients (51 percent) showed a complete response, 18 (34 percent) showed a partial response and eight (15 percent) showed stable disease. Six months later 19 of 34 patients (55.9 percent) had complete tumor response, eight (23.5 percent) had a partial response and seven (20.5 percent) had growing disease. Of the remaining 19 patients, three died, four were lost at follow-up and 12 receive other treatments.

"Patients who still had good liver function and who had tumors in only one lobe of the liver did better with this treatment," said Maurizio Grosso, M.D., chairman of the Department of Radiology at Santa Croce & Carle Hospital, Cuneo, Italy. "We're hopeful that treatment with HepaSphere will be an improvement over traditional chemoembolization."

Embolization without Chemotherapy

Researchers at the European Institute of Oncology in Milan, Italy, are studying using embolization without the chemotherapy for liver cancer. The study included 25 patients with 34 primary liver tumors. All patients received Embozene(TM) microspheres alone, without the addition of any chemotherapeutic agents in the beads. The patients had 35 sessions with the microspheres. After one month follow-up, 18 tumors (52 percent) had shrunk in size while 16 (48 percent) were the same size with no tumor growth detected. In a group of 16 tumors with a follow up ranging between six and 12 months, two tumors (12 percent) completely disappeared, seven tumors (44 percent) continued to shrink, two (12 percent) were stable and five (31 percent) grew, although they were still of a size suitable for new local treatments. To date, 14 patients have had more than one year of follow-up care and 93 percent of them are still alive.

"One concern with embolization is th
'/>"/>

SOURCE International Symposium on Endovascular Therapy
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Stroke Study Reveals a Key Target For Improving Treatment
2. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
3. Reproductive Partners Participates in New IVF Progesterone Delivery System Study
4. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
5. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
6. ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers
7. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
8. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
9. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
10. Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients
11. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... SAN DIEGO, Dec. 17 Suneva Medical, ... that it has signed a multi-million dollar line ... The line of credit facility will be ... only FDA-approved microsphere-enhanced collagen dermal filler on the ... Aesthetic Market growth objectives. ,, "Today Suneva Medical ...
(Date:12/17/2009)... SAN DIEGO, Dec. 17 SpectraScience, Inc., (OTC ... CEO, Jim Hitchin has issued the following letter to ... we are pleased to announce that through the recent ... we are undertaking several initiatives critical to ramping our ... making key additions to our European sales force. We ...
(Date:12/17/2009)... WALTHAM, Mass., Dec. 17 Decision Resources, ... firms focusing on pharmaceutical and healthcare issues, finds ... indicate there is a high need for diabetes ... percent who say there is a high need ... patients favor agents with excellent glucose lowering ability ...
Breaking Medicine Technology:Suneva Medical Signs Multi-Million Dollar Line of Credit Agreement with Western Technology Investment 2Suneva Medical Signs Multi-Million Dollar Line of Credit Agreement with Western Technology Investment 3SpectraScience Releases Shareholder Newsletter 2SpectraScience Releases Shareholder Newsletter 3SpectraScience Releases Shareholder Newsletter 4SpectraScience Releases Shareholder Newsletter 5Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 2Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 3EPA fellow studies effect of mercury in toads 10419 1EPA fellow studies effect of mercury in toads 10419 2Vasogen Inc and IntelliPharmaCeutics Jointly Announce Shareholder Approval of Plan of Arrangement and Merger 14530 1Vasogen Inc and IntelliPharmaCeutics Jointly Announce Shareholder Approval of Plan of Arrangement and Merger 14530 2Vasogen Inc and IntelliPharmaCeutics Jointly Announce Shareholder Approval of Plan of Arrangement and Merger 14530 3OriGene Technologies Acquires Marligen Biosciences 14527 1OriGene Technologies Acquires Marligen Biosciences 14527 2
... 2007 - Genmab A/S (CSE: GEN) announced,today pre-clinical ... have broad potential,to treat cancers that over-express several ... mutations which appear to alter the signaling ability,of ... cancer patients.,Such mutations may be a critical factor ...
... Registry Analysis Published in Journal Heart Finds Taxus Stent,Implantation ... Predictors of Need for Another Procedure, , ... News,Network/ -- An analysis of data from the Western ... Coronary Stent to open a clogged artery were less,likely ...
Other Medicine Technology:New Study Suggests Better Patient Outcomes with CYPHER,Sirolimus-Eluting Coronary Stent than with Taxus Stent in,Real-World Clinical Settings 2New Study Suggests Better Patient Outcomes with CYPHER,Sirolimus-Eluting Coronary Stent than with Taxus Stent in,Real-World Clinical Settings 3
(Date:12/17/2009)... feature is by Devon Herrick, PhD, Senior Fellow at ... often assume they have little control over how much ... cannot be scheduled, doctors prescribe treatments and employers provide ... However, there are many overlooked ways to trim your ... ,, Cut your prescription costs: ...
(Date:12/17/2009)... The National Council on Disability ... JW Marriott Houston, 5150 Westheimer, Houston, TX, beginning at ... at 11:00 a.m. on Thursday, January 21, 2010. This ... believes it is vital to hear from communities around ... for people with disabilities. This meeting will provide another ...
(Date:12/17/2009)... MA Brandeis University selected Jay and Maureen Neitz, the ... use of gene therapy to treat vision disorders, as ... in Vision Sciences. , The award is funded by ... gift from Brandeis graduates Jay Pepose ,75 and Susan ... graduate research fellowships in vision science. , The Neitzes, ...
(Date:12/17/2009)... the particle might someday ease accompanying lung infections , , ... severe pneumonia when infected with the swine flu virus, ... why. , A key to the severity of the ... (TH17), which helps the immune system fight off germs ... in swine-flu patients at 10 Spanish hospitals last summer ...
(Date:12/17/2009)... Studies Important ,for the R&D Informatics Industry, , ... ... Cambridge Healthtech Institute is pleased to announce the participation of ... R&D Informatics Systems conference to be held on February 3-5, ... CA. This meeting has been integrated in the Informatics Channel ...
Breaking Medicine News(10 mins):Health News:Six Ways to Slash Your Health Costs 2Health News:Six Ways to Slash Your Health Costs 3Health News:Six Ways to Slash Your Health Costs 4Health News:National Council on Disability to Hold Houston Meeting to Hear Issues Affecting People With Disabilities 2Health News:Vision researchers Jay and Maureen Neitz to receive first Pepose Award from Brandeis 2Health News:Seven World Leading IT Companies to Sponsor and Speak at CHI's Adopting R&D Informatics Systems, part of 17th International Molecular Medicine Tri-Conference 2Health News:Seven World Leading IT Companies to Sponsor and Speak at CHI's Adopting R&D Informatics Systems, part of 17th International Molecular Medicine Tri-Conference 3
... to provide additional modality integrationsINDIANAPOLIS, March 9 ... pleased to announce the worldwide release of its ... Key features of this release include integrated ECG ... Hemodynamic system. Synapse ProSolv cardiovascular 4.0.1 will ...
... Improvement Plus to Provide Information on Medicare Advantage ... Farmers MarketCOLUMBIA, S.C., March 9 A series ... Medicare beneficiaries with chronic illness maintain a healthy ... Plans designed for their unique needs will be ...
... National Commander of the Disabled American Veterans begins a ... for budget reform legislation to ensure sufficient, timely and ... urging them to reject a contentious proposal that would ... from the government,s side of the ledger to insurance ...
... the latest findings in laboratory, translational and clinical cancer ... therapeutic approaches, as well as strides being made in ... the best advantage of the meeting,s scientific abstracts and ... will be available online at www.aacr.org on Friday, March ...
... Treat Osteosarcoma in More Than 20 YearsIRVINE, Calif., March ... IDMI ) today announced that the European Commission ... (mifamurtide, L-MTP-PE) for the treatment of patients with non-metastatic, ... that typically affects children and young adults. The ...
... author reviews the consequencesROCHESTER, Minn., March 9 ... the treating physician recommends discharge, the consequences may ... the need for readmission, according to a review ... Proceedings. Additionally, the article examines the effect of ...
Other Medicine News:Health News:ProSolv Releases New Cardiovascular Software 2Health News:ProSolv Releases New Cardiovascular Software 3Health News:Free Seminars Offered to South Carolina Seniors with Diabetes and Other Chronic Illnesses 2Health News:Disabled Veterans Leader Presses Issues with Key Lawmakers 2Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 2Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 3Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 4Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 5Health News:Patients Being Discharged Against Medical Advice 2Health News:Patients Being Discharged Against Medical Advice 3
Rapid, visual assay for the presumptive qualitative detection of Respiratory Syncytial Virus (RSV) directly from nasopharyngeal specimens in neonatel and pediatric patients....
Rapid immunochromatographic membrane test for RSV. Accepts nasopharyngeal washes, aspirates, and swabs....
A direct enzyme immunoassay for detection of gr. A rotavirus in fecal specimens....
ELISA for Anti-Proteinase 3 PR3 (cANCA)....
Medicine Products: